Remus Pharmaceuticals IPO

Remus Pharmaceuticals IPO will open for subscription from 17 May 2023. the company aims for an issue size of ₹47.69 Cr through this IPO.


About Company

Incorporated in 2015, Remus Pharmaceuticals is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. It also deals in API (Active Pharmaceutical Ingredient). The company also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries.

The company has cultivated strong and dependable customer relationships ranging from generic distributors, regional distributors, and multinational distributors to Hospitals and Clinics through a responsive distribution network. Remus’ clients are spread in more than 20 countries and its product portfolio consisted of 429 products, as on 31 January 2023. Remus Pharmaceuticals deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.


Basic details about the company

Full nameRemus Pharmaceuticals Limited
SectorTrading
IndustryTrading
Company Websitehttps://remuspharma.com/

The Objective of the Issue

  • To Meet Working Capital Requirements,
  • Funding investments for acquisitions and general corporate purposes,
  • To meet Public Issue Expenses.

IPO Timetable

IPO Opening date17 May 2023
IPO Closing19 May 2023
Basis of Allotment24 May 2023
Initiation Refund25 May 2023
Credit to Demat Account26 May 2023
Listing Date29 May 2023

IPO details

Issue typeBook Built Issue IPO
IPO issue size₹47.69 Cr – 388,000 shares
Fresh Issue₹47.69 Cr – 388,000 shares
Offer for saleNil
Face value₹10 per share
Price Band₹1150 to ₹1229 per share
Lot size100 Shares
Retail Allocation25.03%
Listing ExchangeNSE SME

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)1100₹122,900
Retail (Max)1100₹122,900
HNI (Min)2200₹245,800

Reservation Details

QIB Shares Offered138,750 Shares (35.76%)
NII (HNI) Shares Offered41,625 Shares (10.73%)
Retail Shares Offered97,125 Shares (25.03%)
Anchor Investor Shares Offered110,500 Shares (28.48%)
Market Maker portion19,500 shares

Financial Performance

 FY 2020FY 2021FY 20229M FY 2023
Revenue11.9218.4224.7232.39
Expenses11.6717.8720.8924.92
Net income0.811.033.396.44
(Amount in ₹ Crore)

Valuations & Margins

FY 2020FY 2021FY 2022
EPS8.1210.2633.86
PE ratio33.96 – 36.30
RONW (%)40.1733.6852.64
NAV64.32
ROCE (%)47.7641.9069.99
EBITDA (%)10.428.5119.38
Debt/Equity0.180.090.03

Company Promoters

  • Mr. Arpit Deepakkumar Shah
  • Ms. Roma Vinodbhai Shah
  • Mr. Swapnil Jatinbhai Shah
  • Mrs. Anar Swapnil Shah

Promoter Holding

Pre Issue Share Holding92.82%
Post Issue Share Holding68.37%

Lead Manager(s)

BEELINE CAPITAL ADVISORS PRIVATE LIMITED
807, Phoenix, Opp. Girish Cold Drinks,
Near Vijay Cross Roads, Navrangpura, Ahmedabad -380009
Phone: 079 4840 5357
Email: mb@beelinemb.com
Website: www.beelinemb.com


IPO Registrar

LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park,
Lal Bahadur Shastri Marg, Vikhroli (West),
Mumbai, Maharashtra, India – 400 083
Phone: +91 810 811 4949
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: www.linkintime.co.in


Contact Details

REMUS PHARMACEUTICALS LIMITED
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad – 380054, Gujarat
Phone: +079- 2999 9857
E-mail: cs@remuspharma.com
Website: www.remuspharma.com


Allotment Status

Remus Pharmaceuticals IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.


Final thoughts

Remus Pharmaceuticals IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make wise decisions.

Happy Investing

Leave a Comment

Your email address will not be published. Required fields are marked *